New Blood Thinner Promises to Stop Clots Without Causing Bleeding

Monday, 17 Jun 2013 12:49 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal.
 
Index Ventures, working with GlaxoSmithKline and Johnson & Johnson via an early-stage biotech fund, said on Monday it was investing $11 million in XO1, a new company set up to develop the experimental medicine.
 
Called ichorcumab, the new drug is still miles from reaching the market - clinical trials are only slated to start within the next two years - but the product may create a stir in a commercially important field, given its unusual properties.
 
It was created by scientists at the University of Cambridge and Addenbrooke's Hospital following the observation of a patient in her 50s whose blood appeared unable to clot but who had no major bleeding problems after a head injury in 2008.
 
The researchers pinpointed her unusual response to a unique antibody, which they went on to synthesise.
 
Currently, anticoagulants are used to reduce the risk of heart attacks and strokes, but doctors have to weigh up carefully their benefits against the danger of triggering uncontrolled bleeding.
 
"This antibody can deliver a high degree of anticoagulation without increased bleeding; we've never seen that before," said Jim Huntingdon, a professor at the Cambridge Institute of Medical and one of the scientists behind the project.
 
Warfarin has been a mainstay of anticoagulation therapy for many years. More recently new drugs have been launched, including Boehringer Ingelheim's Pradaxa, Bayer and J&J's Xarelto, and Pfizer and Bristol-Myers Squibb's Eliquis.
 
The $11 million start-up cash for XO1 comes from a $200 million life sciences fund launched last year by Index in an unusual collaboration with GSK and J&J. The fund aims to invest in companies with just one or two projects - a so-called "asset-centric" approach.
 
Under the three-way deal, the venture capital firm controls all investment decisions and the two drugmakers have no preferential rights to acquire any new drugs, although they do get a useful inside view should they wish to compete for assets.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

94 Percent of US Hospitals Unprepared for Ebola

Friday, 24 Oct 2014 16:28 PM

Only about 6 percent of American hospitals have infection control procedures in place to effectively and safely handle E . . .

Osteoporosis Screening Misses Many At Risk: Study

Friday, 24 Oct 2014 16:22 PM

Current osteoporosis screening guidelines and tools fail to identify many younger postmenopausal women at risk for osteo . . .

9 Deadliest Viruses on Earth

Friday, 24 Oct 2014 16:19 PM

A new ranking of the world's deadliest viruses finds flu and Ebola rank among the rogue's gallery of world's nastiest pa . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved